Nephroprotective effect of antihypertensive drugs in essential hypertension

Journal of Hypertension

Volumn 16, Issue 5, 1998, Pages 555-567

  Susic, Dinko ^a   Frohlich, Edward D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Calcium antagonists; Diuretics; Hypertension; Nephrosclerosis; Renal failure; Renoprotection; Vasodilators; blockers

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; CREATININE; DELAPRIL; DILEVALOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; MINOXIDIL; NIFEDIPINE; PROPRANOLOL; PROTECTIVE AGENT; QUINAPRIL; RESERPINE; TRIAMTERENE; VASODILATOR AGENT; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; CREATININE BLOOD LEVEL; ESSENTIAL HYPERTENSION; HUMAN; KIDNEY DISEASE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

EID: 0031971979     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816050-00001     Document Type: Review

References (182)

1. Frohlich ED. Pathophysiology of systemic arterial hypertension. In: Schlant RC, Alexander RW, O'Rourke RA, Robert R, Sonnenblick EH (editors): Hurst's The Heart. New York: McGraw-Hill Inc; 1998, pp. 1635-1650.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke and coronary heart disease, part I: effects of prolonged differences in blood pressure. Evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
3. MacMahon S, Rodgers A, Neal B, Chalmers J. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension 1997; 29:537-538.
4. Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoot R, Amery A. A metaanalysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10:1003-1009.
5. Whelton PK, Perneger TV, Brancati FL, Klag MJ. Epidemiology and prevention of blood pressure-related renal disease. J Hypertens 1992; 10 (suppl 2):S77-S84.
6. United States Renal Data System. USRDS 1994 Annual Data Report. Am J Kidney Dis 1994; 24 (suppl 2):S1-S181.
7. Port FK. End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions. Kidney Int 1995; 4 (suppl 50): S3-S6.
8. Frohlich ED. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997; 29:188-193.
9. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35:6770-6774.
10. Rostand SG, Brown G, Kirk K, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320:684-688
11. Rosansky SJ, Hoover DR, King I, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 1990; 150:2073-2076.
12. National High Blood Pressure Education Program Working Group. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Int Med 1996, 156:1938-1951.
13. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L. Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 1989; 13:120-126.
14. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 33:939-945.
15. Volhard F, Fahr T. Die Brightsche Nierenkrankeit: Klinik, Pathologie und Atlas. Berlin: J. Springer; 1914.
16. Papper S, Vaamode CA. Nephrosclerosis. In: Straus MB, Welt LG (editors): Diseases of the kidney. Boston: Little, Brown and Co; 1971. pp. 735-768.
17. Tracy RE. Blood pressure related separately to parenchymal fibrosis and vasculopathy of the kidney. Am J Kidney Dis 1992; 20:124-131.
18. Kashgarian M. Hypertensive disease and kidney structure. In: Laragh JH. Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management New York: Raven Press; 1995, pp. 433-443.
19. Schwartz GL, Strong CG. Renal parenchymal involvement in essential hypertension. Med Clin N Am 1987; 71:843-858.
20. Sommers SC, Melamed J. Renal pathology of essential hypertension Am J Hypertens 1990; 3:583-587.
21. Darmady EM, Offer J, Woodhouse MA. The parameters of the ageing kidney. J Pathol 1973; 109:195-202.
22. Kaplan C, Pasternack B, Shah H, Gallo G. Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol 1975; 80:227-234.
23. Muirhead EE, Pitcock JA. Histopathology of severe renal vascular hypertension in blacks. Clin Cardiol 1989; 12 (suppl IV):58-65.
24. Heptinstall RH. Malignant hypertension: a study of fifty-one cases. J Pathol Bacteriol 1953; 65:423-437.
25. Kinkaid Smith P. Renal pathology in hypertension and the effects of treatment. Br J Clin Pharmac 1982; 13:107-115.
26. Neuringer JR, Brenner BM. Glomerular hypertension: cause and consequence of renal injury. J Hypertens 1992; 10 (suppl 7):S91-S97.
27. Ritz E, Fliser D, Siebels M. Pathophysiology of renal damage. Am J Hypertens 1993; 6:241S-244S.
28. Anderson S, Brenner BM. The role of nephron mass and of intraglomerular pressure in initiation and progression of experimental hypertensive-renal disorders. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management New York: Raven Press; 1995. pp. 1553-1568.
29. Hilgers KF, Mann JFE. Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Kidney Blood Press Res 1996; 19:254-262.
30. Peters H, Noble NA. Angiotensin II and L-arginine in tissue fibrosis: more than blood pressure. Kidney Int 1997; 51:1481-1486.
31. Rabelnik TJ, Koomans HA. Endothelial function and the kidney. An emerging target for cardiovascular therapy. Drugs 1997; 53 (suppl 1): 11-19.
32. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51:2-15.
33. De Leeuw PW, Kho TL, Falke HE. Hemodynamic and endocrinological profile of essential hypertension. Acta Med Scand 1978; 622 (suppl):5-86.
34. De Leeuw PW, Birkenhäger WH. Renal hemodynamic patterns in essential hypertension. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1995. pp. 1857-1867.
35. London GM, Safar ME, Marchais S. Renal blood flow in man with essential hypertension. Am J Nephrol 1986; 6 (suppl 2):8-11.
36. Dupont AG. Renal hemodynamics in hypertension: effects of antihypertensive drugs. J Hum Hypertens 1993; 7 (suppl 1):42-45.
37. Goldring W, Chasis H, Ranges HA, Smith HW. Effective renal blood flow in subjects with essential hypertension. J Clin Invest 1941; 20:637-653.
38. London GM, Safar ME, Sassard JE, Levenson JA, Simon AC. Renal and systemic hemodynamics in sustained essential hypertension. Hypertension 1984; 6:743-754.
39. Shoback DM, Williams GH, Moore TD, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 1983; 72:2115-2124.
40. Lahera V, Navarro Cid J, Cachofiero V, Garcia-Estan J, Ruilope LM. Nitric oxide, the kidney, and hypertension. Am J Hypertens 1997; 10:129-140.
41. Van Hooft IMS, Grobbee DE, Derkx FHM, de Leeuw PW, Schalekamp MADH, Hofman A. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med 1991; 324:1305-1311.
42. Bianchi G, Picotti GB, Bracchi G, Cusi D, Gatti M, Lupi GP, et al. Familial hypertension and hormonal profile, renal hemodynamics and body fluids of young normotensive subjects. Clin Sci Mol Med 1978; 55:367s-371s.
43. Hollenberg NK, Borucki LJ, Adams DF. The renal vasculature in early essential hypertension: evidence for a pathogenetic role. Medicine 1978; 57:167-178.
44. Messerli FH, de Carvalho JGR, Christie B, Frohlich ED. Systemic and renal hemodynamics in low, normal, and high cardiac output in borderline hypertension. Circulation 1978; 58:441-448.
45. Guyton AC, Hall JE, Coleman TG. The dominant role of the kidneys in long term arterial pressure regulation in normal and hypertensive states. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1995. pp. 1311-1323.
46. Cowley AW, Mattson DL, Lu S. The renal medulla and hypertension. Hypertension 1995; 25:663-669.
47. Arendshorst WJ, Navar GL. Renal circulation and glomerular hemodynamics. In: Schrier RW, Gottschalk LW (editors): Diseases of the kidney. Boston: Little, Brown and Co; 1997. pp. 59-106.
48. Baer PG, Navar LG. Renal vasodilation and uncoupling of blood flow and filtration rate autoregulation. Kidney Int 1973; 4:12-21.
49. Hayashi K, Epstein M, Saruta T. Altered myogenic responsiveness of the renal microvasculature in experimental hypertension. J Hypertens 1996; 14:1387-1401.
50. Navar LG, Ploth DW, Bell PD. Distal tubuloglomerular feedback control of renal hemodynamics and autoregulation. Annu Rev Physiol 1980; 42:557-571.
51. Tolins JP, Shultz P, Raij L. Mechanisms of hypertensive glomerular injury. Am J Cardiol 1988; 62:54G-58G.
52. Parving HH, Jensen HA, Mogensen CE, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; i:1190-1194.
53. 2-microglobulin hyperexcretion in recent severe essential hypertension. J Hypertens 1983; 1:45-51.
54. Alderman MH, Melcher L, Drayer DE, Reidenberg MM. Increased excretion of urinary N-acetyl-beta-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. N Engl J Med 1983; 309:1213-1217.
55. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Anstimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817-821.
56. Kobrin I, Frohlich ED, Ventura HO, Messerli FH. Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med 1986; 146:272-276.
57. Bigazzi R, Bianchi S, Campese VM, Baldan G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61:94-97.
58. Stanton JR, Freis ED. Serum uric acid concentration in essential hypertension. Proc Soc Exp Biol Med 1947; 66:193-194.
59. Ljungman S, Granerus G. The evaluation of kidney function in hypertensive patients. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1995. pp. 1987-2004.
60. Perera GA. Hypertensive vascular disease: description and natural history, J Chron Dis 1955; 1:33-42.
61. Kinkaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Q J Med 1958; 27:117-153.
62. Mamdani BH, Lim VS, Mahurkar SD, Katz AI. Dunea G. Recovery from prolonged renal failure in patients with accelerated hypertension. N Engl J Med 1974; 291:1343-1344.
63. Subcommittee on Definition and Prevalence of the 1984 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension prevalence and the status of awareness, treatment, and control in the United States: final report. Hypertension 1985; 7:457-468.
64. Feld LG, Van Liew JB, Galaske RG, Boylan JW. Selectivity of renal injury and proteinuria in the spontaneously hypertensive rat. Kidney Int 1977; 12:332-343.
65. Komatsu K, Frohlich ED, Ono H, Ono Y, Willis GW. Glomerular dynamics and morphology of aged SHR. Hypertension 1995; 25:207-213.
66. Simons JL, Provoost AP, Anderson SE, Troy JL, Rennke HG, Sandstrom DJ, et al. Pathogenesis of glomerular injury in the fawn-hooded rat: early glomerular capillary hypertension predicts glomerular sclerosis. J Am Soc Nephrol 1993; 3:1775-1782.
67. Steiner RW, Tucker BJ, Gushwa LC, Gifford J, Wilson CB, Blantz RC. Glomerular hemodynamics in moderate glomerular hypertension in the rat. Hypertension 1982; 4:51-57.
68. Dworkin LD, Hosteller TH, Rennke HG, Brenner BM. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest 1984; 73:1448-1461.
69. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85-F93.
70. Scholey JW, Miller PL, Rennke HG, Meyer TW. Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy. Kidney Int 1989; 36:816-822.
71. Perneger TV, Whelton PK, Klag MJ, History of hypertension in patients treated for end-stage renal disease. J Hypertens 1997; 15:451-456.
72. Mountokalakis TD. The renal consequences of arterial hypertension. Kidney Int 1997; 51:1639-1653.
73. Innes A, Johnston PA, Morgan AG, Davison AM, Burden RP. Clinical features of benign hypertensive nephrosclerosis at time of renal biopsy. Q J Med 1993; 86:271-275.
74. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26:861-868.
75. Perneger TV, Nieto J, Whelton PC, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine. JAMA 1993; 269:488-493.
76. Shulman NB, Ford CE, Hall WD, Blaufox MC, Simon D. Langford H on behalf of the Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and the effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension 1989; 13 (suppl ):180-193.
77. Walker GW, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertension members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA 1992; 268:3085-3091.
78. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202:116-122.
79. Veterans Administration Cooperative Study Group on Antihypertensive Agents. II. Effect of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg. JAMA 1970; 213:1143-1152.
80. Samuelsson O, Wikstrand J, Wilhelmsen L, Berglund G. Heart and kidney involvement during antihypertensive treatment. Results from the primary preventive trial in Göteborg, Sweden. Acta Med Scand 1984; 215:305-311.
81. Tomson CRV, Peterson K, Heagerty AM. Does treated essential hypertension result in renal impairment? A cohort study. J Hum Hypertens 1991; 5:189-192.
82. Brown MA, Whitworth JA. Hypertension in human renal disease. J Hypertens 1992; 10:701-712.
83. Iseki K, Ikemiya Y, Fukiyama K. Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int 1996; 49 (suppl 55):S69-S71.
84. Zucchelli P, Zuccala A. Primary hypertension - how does it cause renal failure? Nephrol Dial Transplant 1994; 9:223-225.
85. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American study of kidney disease (AASK) trial. Kidney Int 1997; 51:244-252.
86. Acone D, Cante D, Cillo F, Giordano G, Giordano C. Blood pressure and progression of renal failure in the elderly. Kidney Int 1996; 49 (suppl 55): S75-S77.
87. Frohlich ED, Messerli FH, Dunn FG, Oigman W, Ventura HO, Sundgaard-Riise K. Greater renal vascular involvement in the black patient with essential hypertension. A comparison of systemic and renal hemodynamics in black and white patients. Miner Electrolyte Metab 1984; 10:173-177.
88. Frohlich ED, Messerli FH, Dunn FG. Comparison of renal hemodynamics in black and white patients with essential hypertension. In: Messerli FH (editor): Kidney in essential hypertension. Boston: Martinus Nijhoff Publishing; 1984. pp. 149-156.
89. Perneger TV, Whelton PK, Klag MJ. Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med 1995; 155:1201-1208.
90. Moore MA. End-stage renal disease: a southern epidemic. Southern Med J 1994; 87:1013-1017.
91. Retta TM, Afre GM, Randall OS. Hypertensive renal disease in blacks. Transplant Proc 1993; 25:2421-2422.
92. Earle, KA, Morocutti A, Viberti G. Permissive role of hypertension in the development of proteinuria and progression of renal disease in insulin-dependent diabetes patients. J Hypertens 1997; 15:191-196.
93. Maki DD, Ma JZ, Louis TA, Kasiske BL Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155:1073-1080.
94. Yosheda Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989; 36:626-635.
95. Khlar S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. for the Modification of Diet in Renal Disease Study Group The effects of dietary protein restriction and blood-pressure control of the progression of chronic renal disease. N Engl J Med 1994; 330:877-884.
96. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. 'Strict' blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995; 48:851-859.
97. Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int 1996; 49 (suppl 55):57-62.
98. Wright JT, Kusek JW, Toto RD, Lee JY, Agodoa L, Kirk KA, et al. (for the AASK Pilot Study Investigators). Design and baseline characteristics of participants in the African American study of kidney disease and hypertension (AASK) pilot study. Control Clin Trials 1996; 17 (suppl): 3S-16S.
99. Giatras I, Lau J, Levey AS (for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group). Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127:337-345.
100. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric. non-diabetic nephropathy. Lancet 1997; 349:1857-1863.
101. Griffin KA, Picken M, Bidani AK. Radiotelemetric BP monitonng, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 1994; 46:1010-1018.
102. Navis G, de Zeeuw D, de Jong PE. ACE-inhibitors: panacea for progressive renal disease? Lancet 1997; 349:1852-1853.
103. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-183.
104. The Sixth Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
105. Benstein JA, Feiner HD, Parker M, Dworkin LD. Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 1990; 258:F1675-F1681.
106. Christensen S, Shalmi M, Hansen AK, Marcussen N. Effects of perindopril and hydrochlorothiazide on the long-term progression of lithium-induced chronic renal failure in rats. Pharmacol Toxicol 1997; 80:132-141.
107. Ono H, Ono Y, Frohlich ED. Hydrochlorothiazide exacerbates nitric oxide blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996; 14:823-828.
108. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990; 37:1113-1119.
109. De Leeuw PW on behalf of the European Working Party on High Blood Pressure in the Elderly. Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly Trial. Am J Med 1991; 90 (suppl 3A):45-49.
110. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
111. Brooks DP, Short BG, Cyronak MJ, Contino LC, DiCristo M, Wang YX, et al. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol 1993; 109:581-586.
112. Nordlander M, Havu N. Effects of chronic felodipine treatment on renal function and morphology in SHR. Kidney Int 1992; 41 (suppl 36): S100-S105.
113. Erley CM, Harrer U, Kramer BK, Risler T. Renal hemodynamics and reduction of proteinuria by a vasodilating beta blocker versus an ACE inhibitor. Kidney Int 1992; 41:1297-1303.
114. Ruilope LM, Alcazar JM, Hernandez E, Praga M, Lahera V, Rodicio JL. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994; 45 (suppl 45):S171-S173.
115. Dreslinski GR, Messerli FH, Dunn FG, Suarez DH, Reisin E, Frohlich ED. Hemodynamic, biochemical and reflexive changes produced by atenolol in hypertension. Circulation 1982; 65:1365-1368.
116. Dunn FG, Oigman W, Messerli FH, Dreslinski GR, Reisin E, Frohlich ED. Hemodynamic effects of intravenous labetalol in essential hypertension. Clin Pharmacol Ther 1983; 33:139-143.
117. Frohlich ED, Messerli FH, Dreslinski GR, Kobrin I. Long-term renal hemodynamic effects of nadolol in patients with essential hypertension. Am Heart J 1984; 108:1141-1143.
118. Kohara K, Mikami H, Okuda N, Higaki J, Ogihara T. Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993; 21:975-979.
119. Freis ED, Ragan D, Pilsbury H. Alteration of the course of hypertension in the spontaneously hypertensive rat. Circ Res 1972; 31:1-7.
120. Feld LG, Van Liew JB, Brentjens JR, Boylan JW. Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment. Kidney Int 1981; 20:606-614.
121. Dworkin LD, Grosser M, Feiner HD, Uillian M, Parker M. The renal vascular effect of antihypertensive therapy in uninephrectomized spontaneously hypertensive rat. Kidney Int 1989; 35:790-798.
122. Purkerson ML, Hoffsten PE, Klahr S. Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int 1976; 9: 407-417
123. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
124. Dworkin LD, Feiner HD, Randazzo J. Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy. Kidney Int 1987; 31:718-724.
125. Lafayette RA, Mayer G, Meyer TW. The effect of blood pressure reduction on cyclosporine nephrotoxicity in the rat. j Am Soc Nephrol 1993; 3:1892-1899.
126. Rodicio JL, Praga M, Alcazar JM, Oliet A, Gutierrez-Millet V, Ruilope LM. Effect of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans. J Hypertens 1989; 7 (suppl 7): S43-S47.
127. Jackson B, Johnston CI. The contribution of systemic hypertension to progression of renal failure in the rat remnant kidneys: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. Hypertension 1988; 6:495-501.
128. Dworkin LD. Effects of calcium channel blockers on experimental glomerular injury. J Am Soc Nephrol 1990; 1 (suppl 1):S21-S27.
129. Dworkin LD. Impact of calcium entry blockers on glomerular injury in experimental hypertension, Cardiovasc Drugs Ther 1990; 4: 1325-1330.
130. Dworkin LD, Levin RI, Benstein JA, Parker M, Ullian ME,. Kim Y, et al. Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 1990; 259:F598-F604.
131. Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991; 39:1112-1117.
132. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43:808-814.
133. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI. Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996; 27:245-250.
134. Tolins JP, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990; 16:452-461.
135. Ishimitsu T, Ono H, Ogawa Y, Tsukada H, Oka K, Yagi S. Renoprotective effect of nisoldipme in rats with severe hypertension. J Hypertens 1994; 12:751-759.
136. Saruta T, Kanno Y, Hayashi K, Konishi K. Antihypertensive agents and renal protection: calcium channel blockers. Kidney Int 1996; 49 (suppl 55):S52-S56.
137. Arima S, Ito S, Omata K, Tsunoda K, Yaoita H, Abe K. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int 1996; 49 (suppl 55):S132-S134.
138. Kobayashi S, Hishida A. Effects of a calcium antagonist, manidipine. on progressive renal injury associated with mild hypertension in remnant kidneys. J Lab Clin Med 1995; 125:572-580.
139. Griffin KA, Picken MM, Bidani AK, Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96:793-800.
140. Bidani AK, Griffin KA. Calcium channel blockers and renal protection: is there an optimal dose? J Lab Clin Med 1995; 125:553-555.
141. Demarie B, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113:987-988.
142. Francischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME, Hypertension 1998; 31:795-801.
143. Isshiki T, Amodeo C, Messerli FH, Pegram BL, Frohlich ED. Diltiazem maintains renal vasodilatation without hyperfiltration in hypertension: studies in essential hypertensive man and the spontaneously hypertensive rat. Cardiovasc Drugs Ther 1987; 1:359-366.
144. Isshiki T, Pegram BL, Frohlich ED. Hemodynamic comparison of diltiazem and TA-3090 in spontaneously hypertensive and normal Wistar-Kyoto rats. Am J Cardiol 1988; 62:79-84.
145. Isshiki T, Pegram BL, Frohlich ED. Immediate and prolonged hemodynamic effects to TA-3090 in spontaneously hypertensive and normal Wistar-Kyoto rats. Cardiovasc Drug Ther 1988; 2:539-547.
146. Navar LG, Champion WJ, Thomas CE. Effects of calcium channel blockade on renal vascular resistance responses to changes in perfusion pressure and angiotensin-converting enzyme inhibition in dogs. Circ Res 1986; 58:874-881.
147. Carmines PK, Mitchell KD, Navar LG. Effects of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int 1992; 36 (suppl):S43-S48.
148. Epstein M. Calcium antagonists and renal protection. Arch Intern Med 1992; 152:1573-1584
149. Reams GP, Bauer JH. Effects of calcium antagonists on the hypertensive kidney. Cardiovasc Drugs Ther 1990; 4:1331-1336.
150. ter Wee PM, de Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med 1994; 154:1185-1202.
151. Zanchi A, Brunner HR, Waeber B, Burnier M. Renal hemodynamics and protective effects of calcium antagonists in hypertension. J Hypertens 1995; 13:1363-1375.
152. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stalone C. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42:452-458.
153. Eliahou HE, Cohen D, Hellberg B, Ben-David A, Herzog D, Shechter P. Effect of calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988; 8:285-290.
154. Bigazzi R, Bianchi S, Baldan D, Sgherri G, Baldari G, Campese V. Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am J Hypertens 1993; 6:108-113
155. Gansevoort RT, Slutter WJ, Hemmelder MH, de Zeeuw D. de Jong PE, Antiproteinuric effect of blood pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10:1963-1974.
156. Agewall S, Wikstrand J, Ljungman S. Fagerberg B on behalf of the Risk Factor Intervention Study Group. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1977; 80:164-169.
157. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76:612-619.
158. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM. Mechanism underlying transition from acute glomerular injury to glomerulosclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988; 82:1757-1768.
159. Garcia DL, Renke HG, Brenner BM. Anderson S. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation. J Clin Invest 1987; 80:867-874.
160. Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989; 36:969-977.
161. Beukers JJB, van der Wal A, Hoedemaeker PJ, Weening JJ. Converting enzyme inhibition and progressive glomerulosclerosis in the rat. Kidney Int 1987; 32:794-800.
162. Laffayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90:766-771.
163. Tanaka R, Kon V, Yoshioka T. Ichikawa I, Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 45:537-543.
164. Villa E, Rabano A, Cazes M, Cloarec A, Ruilope L, Garcia-Robles R. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Am J Hypertens 1977; 10:275-281.
165. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1966; 27:176-183.
166. Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int 1966; 49 (suppl 55):S57-S62.
167. Geiger H, Fierlbeck W, Mai M, Ruchti H, Schönfeld V, Dämmrich J, et al. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int 1997; 51:750-761.
168. Raij L. Effects of ACE inhibitors and calcium channel blocker on the development of glomerular sclerosis in models of renal damage. Nephrol Dial Transplant 1995; 10 (suppl 9):23-27.
169. 1-antagonist. Am J Kidney Dis 1991; 18:472-482.
170. Alli C, Lombarde M, Zanni D, Agrati AM, Cassani M, Ganata S. Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. Am J Hypertens 1996; 9:1068-1076.
171. Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int 1996; 49 (suppl 55):S91-S93.
172. Bauer J, Reams GP, Lal SM. Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 1987; 147:1397-1400.
173. Mann JFE, Reisch C, Ritz E. Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. Nephron 1990; 55 (suppl 1):38-42.
174. Rodicio JL, Alcazar JM, Ruilope JL. Influence of converting enzyme inhibition on glomerular filtration and proteinuria. Kidney Int 1990; 38:590-594.
175. Chan J, Critchley JAJH, Tomlison B, Chan TYK, Cockram CS. Antihypertensive and antialbuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17:72-80.
176. Ritz E, Orth SR, Strzelczyk P. Angiotensin converting enzyme inhibitors, calcium channel blockers and their combination in the treatment of glomerular disease. J Hypertens 1997; 15 (suppl 2):21-26.
177. Stefanski A, Amann K, Ritz E. To prevent progression: ACE inhibitors, calcium antagonists or both. Nephrol Dial Transplant 1995; 10:151-153.
178. Münter K, Hergenröder S, Jochims K, Kirchengast M. Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. J Am Soc Nephrol 1996; 7:681-686.
179. Bakris GL, Griffin KA, Picken MM, Bidani AK. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997; 15:1181-1185.
180. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41:912-919.
181. Bakris GL, Williams B. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 1995; 13 (suppl 2):S95-S101.
182. Simeon G, Bakris GL. Socio-economic impact of diabetic nephropathy: can we improve the outcome? J Hypertens 1997; 15 (suppl 2): S77-S82.